Zeus Hygia Lifesciences has signed a Memorandum of Understanding (MOU) with UK-based Patch House Labs to jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats for global markets.
The strategic collaboration aims to transform Zeus Hygia’s proprietary, clinically validated nutraceutical ingredients into transdermal delivery systems (TDDS), offering improved bioavailability, sustained release, and enhanced consumer compliance compared to conventional oral supplements.
Under the partnership, the companies will initially focus on converting three of Zeus Hygia’s branded ingredients into patch-based formats. These include Metaberine®, a low-dose berberine formulation positioned for metabolic health and glucose management; STADICE®, an enriched mango extract designed to support cognitive wellness and memory; and Grantria®, a pomegranate extract targeted at beauty-from-within and menopausal health applications.
Transdermal delivery systems are increasingly gaining traction within the wellness sector due to their ability to bypass first-pass metabolism and gastrointestinal degradation. By enabling controlled release of active compounds through the skin, TDDS formats can enhance therapeutic potential while offering greater convenience to consumers.
The collaboration reflects a broader industry trend where ingredient innovation and delivery technology are converging to meet growing demand for convenient, effective, and science-backed wellness solutions. As consumer preferences shift toward next-generation supplement formats, transdermal nutraceuticals are emerging as a promising alternative to traditional capsules and tablets.
The MOU reinforces Zeus Hygia’s strategy to expand its branded ingredient portfolio into advanced delivery platforms while strengthening Patch House Labs’ position in the premium topical supplement segment.
